The agenda covers gene therapy, gene edited cell therapies, stem cells & regenerative medicine.
Heart disease, even while being curable comes as one of the biggest threats to one’s health in today’s world.
Heart disease is one of the biggest threats to your and my health. It’s the leading cause of death around the world, kills one in six men and one in six women, and afflicts 2.3 million people in the UK alone.
Ajan Reginald was born in Kandy, Sri Lanka. When Ajan was five his family emigrated to England because Ajan’s father got a job as a doctor in NHS. His father is a Medical school lecturer (Warwick Uni) and his mother is a clinical psychotherapist. The family settled in Coventry and Ajan first gained entrance to King Henry School and then won a scholarship to Rugby School.
Ajan Reginald immigrated with his family to England from Sri Lanka. Ajan Reginald belongs to a family of medical professionals. Ajan Reginald is the Co-Founder and Chief Executive Officer of Celixir in United Kingdom (formerly Cell Therapy Limited).
Scientists and researchers have been quite successful in identifying, growing and differentiating stem cells and developing effective stem cell therapies. But now, especially as many clinical trials are moving beyond animal testing to human testing, it’s important to consider the best methods of delivery.
The Medicines and Healthcare Products Regulatory Agency has issued a green light allowing Celixir to carry out a potentially pivotal Phase IIb human clinical trial with its stem cell therapy Heartcel.
It was like two years back, when Ajan Reginald, the founder, CEO of Celixir, spoke to IntelligentHQ.com about all the present challenges and opportunities within the healthcare industry.
Ajan (Kellogg, 2014) is the highflying CEO and co-founder with Nobel Laureate Sir Martin Evans in 2009, of a stem cell health company called Celixir.
Celixir has agreed a deal with the Daiichi Sankyo that will see all of its advanced cell therapy medicine developed and distributed in the Japanese markets.